Efecto de altos niveles de hierro y molibdeno sobre la nutrición del cobre en vacas mestizas / High levels of dietary iron and molybdenum on copper nutrition in cross bred cows

Para estudiar el efecto de altos niveles de hierro (Fe) y molibdeno (Mo) sobre la nutrición del cobre (Cu), 20 vacas vacías, mestizas Bos taurus x Bos indicus, de 394 kg PV y de más de dos partos, fueron distribuidas según un diseño completamente aleatorizado en los siguientes tratamientos: (1) Testigo (T): 10 ppm Cu; (2) Mo: 10 ppm Cu y 20 ppm Mo; (3) Fe: 10 ppm Cu y 1000 ppm Fe; (4) MoFe: 10 ppm Cu y 1000 ppm Fe y 20 ppm Mo. Las vacas fueron alimentadas ad libitum con pasto de corte (Panicum maximun y Andropogun gayanus), 1,5 kg de alimento por animal día -1 (harina de maíz: 95 por ciento; urea: 5 por ciento) que contenía los minerales en las proporciones indicadas. Se tomaron muestras de suero sanguíneo para determinar Cu, Fe y la actividad de la ceruloplasmina. A través de biopsias, se tomaron muestras del tejido hepático cada 28 días, durante 192 días, para determinar la concentración de Cu, Fe y Mo. El consumo de pasto estuvo alrededor de 10 kg MS/animal día -1. El peso vivo no presentó diferencias entre tratamientos con valores de 385; 353; 396 y 382, kg para T, Mo, Fe, MoFe, respectivamente. La concentración de Cu sérico (µg ml-1) fue de 0,81; 0,67; 0,50 y 0,71, respectivamente para el mismo orden de los tratamientos, siendo Fe el más bajo (P<0,05). Para el Fe sérico, se observaron diferencias significativas entre los tratamientos (P<0,05), con valores de 1,49; 1,67; 2,08 y 1,93 µg ml -1, para el testigo, Mo, Fe y MoFe, respectivamente. Los valoresde Cp (absorbancia) fueron 0,093; 0,085; 0,084 y 0,087, para el testigo, Mo, Fe y MoFe, respectivamente, sin diferencias significativas entre tratamientos. Los niveles de Cu hepático fueron diferentes (P<0,01) entre tratamientos, con valores más altos (mg kgMS-1) para T (71,9) y más bajos para Mo (26,6), Fe (30,8) y MoFe (31,4). La concentración de Fe en el hígado registró valores (mg kgMS-1) de 559,0; 513,3; 559,8 y 797,3para T, Mo, Fe y MoFe, respectivamente, sin diferencias significativas...

To evaluate the effect of high levels of iron (Fe) and molybdenum (Mo) on copper (Cu) nutrition, 20 dry cross bred cows, Bos Taurus x Bos indicus, of 394 kg BW, with no less than two calving, were assigned to the following treatments: (1) Control (C); 10 ppm Cu(2); Mo 10 ppm + 20ppm Cu (Mo); (3) 10ppm Cu+ 1000 ppm Fe (Fe); and (4) 10 ppmCu+ 1000 ppm Fe+ 20 ppm Mo ( MoFe). Cows were fed chopped forage ad libitum (Panicum maximum and Andropogun gayanus) and 1.5 kg concentrate feed (corn meal, 95% and urea, 5%) containing minerals in the proportions as previously indicated. Serum samples were taken every 28 days for Cu, Fe and cerulopasmine (Cp) activity. Liver sample, via biopsy, at the same time intervals, were also taken to measure Cu, Fe and Mo concentrations. The experiment lasted 192 days. Body weights were not affected by treatments: 385; 353; 396 and 382 kg, respectively for T, Cu, Fe,and MoFe. Copper serum concentration values (µg ml-1) were 0.81, 0.67, 0.50 and 0.71, respectively for the same order, being Fe the lowest (P<0.05). Ceruloplasmine absorbancy values were not different among treatments. Liver copper concentration values were significantly different (P<0.05) among treatments, with higher value (mg KgMS-1) for T (71.9) and lower for Mo (26.6), Fe (30.8) and MoFe (31.4). Liver iron concentration (mg kgMS-1) values were not different among treatments, with values of 559.0, 513.3, 559.8, and 797.3 respectively for C, Mo, Fe and MoFe. Liver Mo take up (mg kgMS-1) was greater (P<0.01) for Mo treatment (19.9) and MoFe (15.8) in relation to T (1.7) and Fe (1.9). Results indicate that high levels of Mo and Fe decreased liver copper, below critical levels. However, the reduction of liver copper was no associated with clinical sign of copper efficiency. Probably lower levels of liver copper are required to show changes in ceruloplasmine and blood serum concentrations as well as other biochemical changes at tissue level...

[The use of ceruloplasmin in combination with adjuvant polychemotherapy in stomach cancer]. / Primenenie tseruloplazmina v sochetanii s ad''iuvantnoi polikhimioterapiei pri rake zheludke.

Ceruloplasmin as a modulator was used for the first time in the clinical practice in 30 patients with gastric cancer in the course of postoperative intraabdominal adjuvant chemotherapy. It was established that ceruloplasmin was well tolerated by the patients and its use during polychemotherapy is accompanied by normalization of the levels of natural ceruloplasmin and iron in the blood serum that are usually reduced in patients with gastric cancer, reduces activation of lipid peroxidation and improves the course of postoperative period. Ceruloplasmin possesses a week immunomodulating action in polychemotherapy which is expressed in the increase of the percentage content of T-lymphocytes. Use of ceruloplasmin tended to improve the functional state of the cardiovascular system.

Clinical results on the use of human ceruloplasmin in aplastic anemia.

Frequent blood transfusions are necessary in aplastic anemia because of decreased hematopoietic function. In order to maintain the hemoglobin level and to decrease the need for blood transfusion, human ceruloplasmin was used for the treatment of 73 patients with aplastic anemia. A marked beneficial effect was obtained in 16 cases. The treatment was moderately effective in 17 cases, slightly effective in eight cases, and ineffective in 32 cases. The usual dose of ceruloplasmin was 15 mg/day, but it was varied according to symptoms. Side effects were minimal when ceruloplasmin was administered by slow intravenous injection.

Talidomida efeito sobre a ceruloplasmina serica / Thalidomide: effect on the serum ceruloplasmin

Ceruloplasmin enzymatic activity was determined in rat sera using p-phenylenediamine as substrate at pH 5.4. The levels of the oxidase in the animais treated with thalidomide by perenteral or gatro-intestinal routes were not statistically different from the values obtained in the control rats.